An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model

Thrombosis Research

Volumn 98, Issue 4, 2000, Pages 333-342

  Nagashima, Mariko ^a   Werner, Matthias ^a   Wang, Manping ^a   Zhao, Lei ^a   Light, David R ^a   Pagila, Rene ^a   Morser, John ^a   Verhallen, Peter ^a  

^a BAYER AG   (Germany)

Author keywords

Potato carboxypeptidase inhibitor; TAFI; Thrombolysis

Indexed keywords

ALTEPLASE; CARBOXYPEPTIDASE B; CARBOXYPEPTIDASE B INHIBITOR; ENZYME INHIBITOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG PURITY; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANTIPLASMIN; CARBOXYPEPTIDASE U; CARBOXYPEPTIDASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; FIBRIN; FIBRINOGEN; FIBRINOLYSIS; INFUSIONS, INTRAVENOUS; PLANT PROTEINS; PLASMINOGEN; RABBITS; SOLANUM TUBEROSUM; THROMBIN; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; VENOUS THROMBOSIS;

EID: 0034657826     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00184-5     Document Type: Article

References (38)

1. Hendriks D., Scharpe S., van Sande M., Lommaert M.P. Characterization of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem. 27:1989;277-285.
2. Campbell W., Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun. 162:1989;933-939.
3. Eaton D.L., Malloy B.E., Tsai S.P., Henzel W., Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase b from human plasma. J Biol Chem. 266:1991;21833-21838.
4. Wang W., Hendriks D.F., Scharpe S.S. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem. 269:1994;15937-15944.
5. Bajzar L., Manuel R., Nesheim M.E. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem. 270:1995;14477-14484.
6. Tan A.K., Eaton D.L. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry. 34:1995;5811-5816.
7. Nesheim M.E., Wang W., Boffa M., Nagashima M., Morser J., Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost. 78:1997;386-391.
8. Bajzar L., Morser J., Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem. 271:1996;16603-16608.
9. Bajzar L., Nesheim M.E., Tracy P.B. The profibrinolytic effect of protein C in clots formed from plasma is TAFI-dependent. Blood. 88:1996;2093-2100.
10. Sakharov D.V., Plow E.F., Rijken D.C. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem. 272:1997;14477-14482.
11. Hosaka Y., Takahashi Y., Ishii H. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma carboxypeptidase B. Thromb Haemost. 79:1998;371-377.
12. Bajzar L., Nesheim M., Morser J., Tracy P.B. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of TAFI. J Biol Chem. 273:1998;2792-2798.
13. Mosnier L.O., von dem Borne P.A., Meijers J.C.M., Bouma B.N. Plasma TAFI levels influence the clot lysis in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost. 80:1998;829-835.
14. Minnema M.C., Friederich P.W., Levi M., von dem Borne P.A.K., Mosnier L.O., Meijers J.C.M., Biemond B.J., Hack C.E., Bouma B.N., ten Cate H. Enhancement of rabbit jugular vein thrombolysis by neutralization of Factor XI. J Clin Invest. 101:1998;10-14.
15. Refino C.J., Schmitt D., Pater C., Eaton D., Bunting S. A carboxypeptidase inhibitor markedly improves the potency of t-PA in vivo. Fibrinolysis & Proteolysis. 12(Suppl 1):1998;29.
16. Carmeliet P., Stassen J.M., Schoonjans L., Ream B., vanden Oord J.J., De Mol M., Mulligan R.C., Collen D. Plasminogen activator inhibitor gene-deficient mice. J Clin Invest. 92:1993;2756-2760.
17. Levi M., ten Cate H., Bauer K.A., van der Poll T., Edgington T.S., Buller H.R., van Deventer S.J.H., Hack C.E., ten Cate J.W., Rosenberg R.D. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibodies in chimpanzees. J Clin Invest. 93:1994;114-120.
18. Paloma M.J., Paramo J.A., Rocha E. Endotoxin-induced intravascular coagulation in rabbits. Effect of tissue plasminogen activator vs urokinase on PAI generation, fibrin deposits and mortality Thromb Haemost. 74:1995;1578-1582.
19. Kato K., Shinagawa N., Hayakawa T., Takeyama H., Campbell W., Okada H. Changes in arginine carboxypeptidase (CPR) activity in stressed rats. Pathophysiology. 1:1994;131-136.
20. Glaser C.B., Morser J., Clarke J.H., Blasko E., McLean K., Kuhn I., Chang R.-J., Lin J.-H., Vilander L., Andrews W.H., Light D.R. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. J Clin Invest. 90:1992;2565-2573.
21. Zhao L., Morser J., Bajzar L., Nesheim M., Nagashima M. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms. Thromb Haemost. 80:1998;949-955.
22. Collen D., Stassen J.M., Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. J Clin Invest. 71:1983;368-376.
23. Skidgel R.A. Structure and function of mammalian zinc carboxypeptidases. Hooper N.M. Zinc Metalloproteases in Health and Diseases. 1996;241-283 Tayler and Francis Ltd, London.
24. Hortin G.L., Gibson B.L., Fok K.F. α2-Antiplasmin's carboxy-terminal lysine residue is a major site of interaction with plasmin. Biochem Biophys Res Commun. 155:1988;591-596.
25. Collen D. On the regulation and control of fibrinolysis. Thromb Haemost. 43:1980;77-89.
26. Castellino F.J., Urano T., De Serrano V., Morris J.P., Chibber B.A.K. Control of human plasminogen activation. Haemostasis. 18(Suppl 1):1988;15-23.
27. Gurewich V., Liu J.-N., Pannell R. The intrinsic lysis concept. Ann NY Acad Sci. 667:1992;224-232.
28. Verstraete M. The fibrinolytic system. From petri dishes to genetic engineering Thromb Haemost. 74:1995;25-35.
29. Plow E.F., Allampallam K., Redlitz A. The plasma carboxypeptidases and the regulation of the plasminogen system. Trends Cardiovasc Med. 7:1997;71-75.
30. Suenson E., Lutzen O., Thorsen S. Initial plasmin-degradation of fibrin as the basis of a positive feedback mechanism in fibrinolysis. Eur J Biochem. 140:1984;513-522.
31. van Zonneveld A.J., Veerman H., Pannekoek H. On the interaction of the finger and kringle-2 domain of t-PA with fibrin. Inhibition of kringle-2 binding to fibrin by epsilon-amino caproic acid. J Biol Chem. 261:1986;14214-14218.
32. Broze G., Higuchi D.A. Coagulation-dependent inhibition of fibrinolysis. Role of carboxy-peptidase-U and the premature lysis of clots from hemophilic plasma Blood. 88:1996;3815-3823.
33. von dem Borne P.A., Meijers J.C.M., Bouma B.N. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood. 86:1995;3035-3042.
34. von dem Borne P.A., Bajzar L., Meijers J.C.M., Nesheim M.E., Bouma B.N. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest. 99:1997;2323-2327.
35. Sakata Y., Aoki N. Significance of cross-linking of α2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest. 69:1982;536-542.
36. Jansen J.W.C.M., Haverkate F., Koopman J., Nieuwenhuis H.K., Kluft C., Boschman Th.A.C. Influence of factor XIII activity on human whole blood clot lysis in vitro. Thromb Haemost. 57:1987;171-175.
37. Polgár J., Léránt I., Muszbek L., Machovich R. Thrombomodulin inhibits the activity of factor XIII by thrombin. Thromb Res. 43:1986;585-590.
38. Klement P., Liao P., Bajzar L. An inhibitor of activated TAFI enhances thrombolysis in vivo. Blood. 92(Suppl 1):1998;709a.